EXHIBIT 10.3

Portions of this Exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of
1934. Such omissions are designated as ***.

AMENDMENT NO.3 TO

LICENSE AGREEMENT

DATED AS OF APRIL 13, 2002

BY AND BETWEEN

UNIGENE LABORATORIES,
INC.

AND

SMITHKLINE BEECHAM CORPORATION

This Amendment No. 3 (Amendment No. 3) dated as of 23 Sept., 2004
(Amendment Date), to the License Agreement, entered into as of the 13th of April, 2002, and amended on January 16, 2003 and October 14, 2003 (referred to hereinafter as the Agreement), by and between Unigene
Laboratories, Inc. (Unigene), a Delaware corporation, and SmithKline Beecham Corporation, a GlaxoSmithKline company (GSK), a Pennsylvania corporation.

RECITALS:

WHEREAS, GSK and Unigene entered into the Agreement to provide for the
license grant by Unigene to GSK of certain Licensed Technology (as defined in the Agreement) to discover, develop, make, have made, market, sell and import certain Licensed Products (as defined in the Agreement) throughout the world under the
Unigene Patent Rights (as defined in the Agreement) and Unigene Know-How (as defined in the Agreement); and

WHEREAS, GSK and Unigene have
also entered into a Phase I Clinical Manufacture and Supply Agreement dated November 20, 2002 (the Phase I Agreement); and

WHEREAS, pursuant to Section 11.10 of the Agreement, the Parties to the Agreement may, by written instruments specifically referring to and executed in the same manner as the Agreement, amend the Agreement; and

WHEREAS, the Parties hereto desire to amend the Agreement as provided herein, and any capitalized terms used herein shall have the meaning set forth in
the Agreement;

NOW THEREFORE, for and in consideration of the premises and the mutual promises and benefits contained herein, GSK and
Unigene hereby agree as follows:

1. Exhibit C to the Phase I Agreement (Cost of Goods) is hereby amended to add the 2004 and 2005 Cost of
Goods set forth in Appendix A to this Amendment No. 3.



---

2. Exhibit A to the Phase I Agreement (Current Manufacturing Process) is hereby amended by replacing the
existing Process Flow Diagram-PTH with the Process Flow Diagram-PTH set forth in Appendix B to this Amendment No. 3.

3. Appendix B to
the Agreement (the WorkPlan) is hereby amended to add the activities regarding API set forth in Appendix C to this Amendment No. 3 at the FTE costs set forth in Appendix C to this Amendment No. 3.

4. Article 1 of the Phase I Agreement is hereby amended to add the following new section:

1.25. Commercially Reasonable Efforts means, with respect to a Party, the efforts and resources which would be used (including without limitation
the promptness in which such efforts and resources would be applied) by that Party consistent with its normal business practices, which in no event shall be less than the level of efforts and resources standard in the pharmaceutical industry for a
company similar in size and scope to such Party, with respect to a product or potential product at a similar stage in its development or product life taking into account efficacy, safety, commercial value, the competitiveness of alternative products
of third parties that are in the marketplace or under development, and the patent and other proprietary position of such product.

5.
Section 2.3 of the Phase I Agreement is hereby amended by replacing the current language with the following language in lieu thereof:

Unigene shall supply GSK at least four (4) batches of API (two (2) batches shall be cGMP grade and two (2) shall be process development batches). Unigene shall use its Commercially Reasonable Efforts to achieve a fermentation
batch yield of ***. The Parties agree and acknowledge that one Changeover shall be required before supply of the first batch. Any batches in excess of four (4) shall be supplied pursuant to the terms of this Agreement, including but not limited
to, Article 4.6(b).

6. Article 2 of the Phase I Agreement is hereby amended to add the following new section:

2.9. GSK Equipment. In order to support the manufacture of GSK material requirements, GSK will purchase and Unigene will install *** Columns,
including spare parts therefore (the Columns), in the facility. The Parties agree that the Columns are the property of GSK and will be used solely for the purpose of manufacturing GSK material requirements. Following receipt of written
notification from GSK that Unigene will no longer be producing API for GSK for any purpose, GSK will notify Unigene of whether GSK intends to: a) keep the Columns and have them removed from the Unigene facility(ies) or, b) offer the Columns for sale
to Unigene. The parties will negotiate in good faith a price for the purchase of the Columns by Unigene, said price not to exceed the depreciated value of the Columns (straight-line depreciation over ten (10) years) minus



- 2 -



---

Unigenes actual FTE costs for their assembly and installation/operation qualification. In the event GSK elects to keep the Columns and have them
removed from the Unigene facility or, if the parties are unable to agree on a good faith purchase price, GSK will: a) reimburse Unigene for its actual FTE costs incurred for assembly and installation/operation qualification and, (b) reimburse
Unigene for its actual FTE costs of disassembling and unpacking the Columns prior to their return and, c) pay for any associated shipping costs incurred to ship the Columns via a GSK-approved carrier.

7. For the avoidance of doubt, the Parties agree and acknowledge that GSK has ordered the Columns identified in Section 6 of this Amendment and the
Columns will be shipped directly to Unigene for installation.

8. Section 11.1 of the Phase I Agreement is hereby is amended to
replace the words twenty-four (24) months with the words thirty (30) months.

9. This Amendment
No. 3 may be executed in two (2) or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be duly executed by their authorized representatives as of the Amendment Date.



|                           |  |                          |  |                                                           |  |        |  |                  
|-------------------------- |  | ------------------------ |  | --------------------------------------------------------- |  | ------ |  | -----------------
|UNIGENE LABORATORIES, INC. |  |                          |  | SMITHKLINE BEECHAM CORPORATION, a GlaxoSmithKline Company
|                           |  |                          |  |                                                          
|By:                        |  | /s/ Ronald S. Levy       |  |                                                           |  | By:    |  | /s/ John Knighton
|Name:                      |  | Ronald S. Levy           |  |                                                           |  | Name:  |  | John Knighton    
|Title:                     |  | Executive Vice President |  |                                                           |  | Title: |  | Director, GSK    



- 3 -



---

Appendix A

COST OF GOODS

The Cost of Goods*for API manufactured pursuant to the Agreement for the 2004 and 2005 calendar years is:

***

***



|* | Cost of Goods is subject to revisions as set forth in Article 2 of the Agreement.
|- | ---------------------------------------------------------------------------------



- 4 -



---

Appendix B

CURRENT MANUFACTURING PROCESS  PROCESS FLOW DIAGRAM

PROCESS FLOW DIAGRAM - PTH



|                         |  |       |  |                           |  |                                                             
|------------------------ |  | ----- |  | ------------------------- |  | ------------------------------------------------------------
|Process Steps            |  | Step# |  | Molecular Form of Product |  | Batch Records                                               
|Fermentation             |  | 1     |  |                           |  | *** (Shake Flask Inoculum), ***
(Fermentation to Harvesting)
|Harvest                  |  | 2     |  |                           | 
|***                      |  | 3     |  | rPTH-***                  |  | *** (Capture)                                               
|***                      |  | 4     |  |                           |  | *** (Purified PTH)                                          
|***                      |  | 5     |  |                           | 
|***                      |  | 6     |  |                           | 
|***                      |  | 7     |  | rPTH                      | 
|***                      |  | 8     |  |                           | 
|***                      |  | 9     |  |                           | 
|***                      |  | 10    |  |                           |  | *** (Parathyroid Hormone)                                   
|Bulk Parathyroid Hormone |  |       |  |                           |  |                                                             



---

Appendix C

WORKPLAN OF UNIGENE ACTIVITIES AND FTE REQUIREMENTS



|                                                                                                                         |  |                  |  |          |    |  |              |    |  |                 |   
|------------------------------------------------------------------------------------------------------------------------ |  | ---------------- |  | -------- | -- |  | ------------ | -- |  | --------------- | --
|                                                                                                                         |  | ESTIMATEDPERIOD  |  | DURATION |    |  | UNIGENESTAFF |    |  | MAXIMUMCOST ($) |   
|DEVELOPMENT ACTIVITY PRIOR TO PHASE II                                                                                   |  |                  |  |          |    |  |              |    |  |                 |   
|MANUFACTURING CAMPAIGN                                                                                                   |  |                  |  |          |    |  |              |    |  |                 |   
|Replacement of *** with *** and Optimization of *** reaction                                                             |  | May 04 July 04  |  | 7 weeks  |    |  | *            | ** |  | *               | **
|                                                                                                                         |  |                  |  |         
|Development of *** to replace *** in process steps *** and ***                                                           |  | July 04  Sep 04 |  | 9 weeks  |    |  | *            | ** |  | *               | **
|                                                                                                                         |  |                  |  |          |    |  |              |    |  |                 |   
|SUB TOTAL                                                                                                                |  |                  |  | 16 weeks |    |  |              |    |  | *               | **
|TECHNOLOGY TRANSFER[1]                                                                                                   |  |                  |  |          |    |  |              |    |  |                 |   
|                                                                                                                         |  |                  |  |         
|Unigene to work with GSK on validation and technology transfer prior to phase III clinical studies.                      |  | TBC              |  | *        | ** |  | *            | ** |  | *               | **
|                                                                                                                         |  |                  |  |         
|Unigene to work with GSK on NDA preparation, validation and technology transfer at or beyond phase III clinical studies. |  | TBC              |  | *        | ** |  | *            | ** |  | *               | **



|[1] | Timing of technology transfer dependent on manufacturing strategy to be determined. The two options are mutually exclusive and NOT additive.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------



- 6 -